Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of FP-1039 in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors

NCT00687505 is registered in ClinicalTrials.gov with Five Prime Therapeutics, Inc. as lead sponsor.

NCT NCT00687505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00687505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of FP-1039 in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors
Lead sponsor
Five Prime Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2008
Completion date
June 30, 2011
Enrollment
39 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer